Pemphigus Vulgaris Therapeutics Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 296.35 Million |
| Market Size (2030) | USD 402.23 Million |
| CAGR (2025 - 2030) | 6.30% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Pemphigus Vulgaris Therapeutics Market Analysis
The Pemphigus Vulgaris Therapeutics Market size is estimated at USD 296.35 million in 2025, and is expected to reach USD 402.23 million by 2030, at a CAGR of 6.3% during the forecast period (2025-2030).
Certain factors propelling market growth include the increasing prevalence of pemphigus vulgaris, growing research and development, and manufacturers increasingly focusing on drug development.
As more individuals are diagnosed with pemphigus vulgaris, the need for advanced therapies grows, prompting pharmaceutical companies to invest in research and development. This leads to the introduction of innovative treatments and improved patient outcomes. For instance, according to the article published by The Pan Medical African Journal in July 2022, pemphigus vulgaris, accounting for over 80% of all cases, is the predominant form of pemphigus, particularly noted for its oral lesions.
Additionally, according to the Journal of Oral Medicine and Pain in December 2023, PV is the most common autoimmune disease in South Korea. It is more prevalent in several Asian countries, including South Korea. Individuals aged 40-60, particularly women, exhibit a higher incidence rate of pemphigus vulgaris. Therefore, the increasing prevalence of pemphigus vulgaris will drive the market by elevating demand for effective treatments, leading to more significant investment in research and development. This growing patient population enhances awareness and promotes early diagnosis, resulting in a robust market for innovative therapies. In conclusion, the rising incidence of autoimmune diseases directly fuels the growth of the PV therapeutics market by necessitating better and more accessible treatment options.
Moreover, as researchers focus on understanding disease mechanisms, they are discovering new targets for therapy, leading to the development of innovative treatments such as biologics and targeted immunotherapies. Increased R&D efforts also foster collaboration between academic institutions and pharmaceutical companies, enhancing the speed and efficacy of bringing new therapies to market. For instance, according to a study published by the Journal of Oral Medicine and Pain in December 2023, research concluded that Pemphigus vulgaris (PV) and pemphigus foliaceus together constitute 90%-95% of all pemphigus diagnoses. In addition, patients with desquamative gingivitis lesions face longer diagnostic delays compared to those with ulcers and erosions. Hence, heightened research and development activities will propel the pemphigus vulgaris therapeutics market by generating novel treatment options and accelerating the availability of effective patient therapies.
Furthermore, manufacturers are focusing on securing approval to expand globally. For instance, in June 2023, AstraZeneca secured approval in China for Soliris (eculizumab) to treat adult patients with refractory generalized myasthenia gravis (gMG) who are favorable for the anti-acetylcholine receptor (AChR) antibody. Soliris stands as the sole complement inhibitor approved for gMG treatment in China. The National Medical Products Administration (NMPA) in China based its clearance on comprehensive Phase III REGAIN trial findings.
Due to the aforementioned factors, such as the increasing prevalence of pemphigus vulgaris, rising research and development activities, and key players focusing on development, as well as approval from regulatory bodies, the market is expected to continue to grow over the coming years.
However, stringent FDA guidelines for drug approvals may restrain the market in the forecast period.
Pemphigus Vulgaris Therapeutics Market Trends
Corticosteroids Segment Expected to be the Fastest-growing Treatment Segment in the Forecast Period
Corticosteroids are anti-inflammatory medications commonly used in the pemphigus vulgaris therapeutics market to reduce immune system activity and alleviate symptoms. They help control the blistering and inflammation associated with the condition by suppressing the autoimmune response that targets the skin and mucous membranes. Corticosteroids can be administered topically, orally, or intravenously, depending on the severity of the disease and the patient's needs.
For instance, as per the article published by Hindawi in September 2022, PV treatment relies on immunosuppression. While topical corticosteroids are effective for limited cases of PV, mainly when lesions are confined to the oral cavity, systemic corticosteroids remain the primary treatment for these oral lesions. As per the same source, corticosteroids primarily influence T-cell activation, resulting in significant immunosuppressive effects. They inhibit cytokine release, thereby reducing molecule production. Furthermore, corticosteroids cause transient lymphocytopenia by altering lymphocyte recirculation and inducing lymphocyte death.
Additionally, there is no standardized guideline for corticosteroid use after rituximab therapy; clinicians may prescribe corticosteroids in varying dosages and schedules based on individual patient needs and experiences. This variability can lead to an increased demand for corticosteroid medications as healthcare providers seek to find effective regimens for managing residual symptoms. For instance, according to the Health Science Reports published in June 2022, several studies in literature now consolidate the efficacy of rituximab in treating PV in clinical practice. However, after rituximab maintenance, there is no standardized protocol for systemic corticosteroids; the approach largely hinges on clinical experience.
Moreover, corticosteroids are essential in treating childhood pemphigus vulgaris, effectively reducing inflammation and controlling blister formation. Their rapid action is crucial for managing symptoms in pediatric patients, where timely intervention is vital. For instance, according to the Indian Journal of Dermatology, Venereology, and Leprology in July 2024, in treating childhood pemphigus vulgaris, systemic corticosteroids, combined with steroid-sparing agents, serve as the primary therapeutic approach. Therefore, the use of corticosteroids in treating childhood pemphigus vulgaris is poised to drive growth in the corticosteroid segment of the pemphigus vulgaris therapeutics market in the forecast period.
North America Expected to Hold a Significant Market Share
Some factors driving market growth in North America include financial programs to provide funding, the growing prevalence of pemphigus vulgaris, and rising research studies on pemphigus vulgaris therapeutics in the market.
Financial assistance programs for individuals living with pemphigus vulgaris play a crucial role in driving the therapeutics market by addressing the high costs associated with treatment. Many patients face significant financial barriers when accessing necessary medications, which can lead to treatment non-adherence and worsened health outcomes. For instance, in January 2023, The PAN Foundation launched a financial assistance program for individuals diagnosed with pemphigus vulgaris, offering up to USD 6,600 annually to qualifying patients. This initiative by PAN aims to enhance accessibility to essential care for more individuals. Therefore, financial assistance programs improve access to pemphigus vulgaris therapies, promoting adherence and better health outcomes, which are anticipated to fuel the market's growth in the forecast period.
Moreover, the increasing prevalence of pemphigus vulgaris will drive growth in the therapeutics market due to the rising number of diagnosed cases, which boosts the demand for effective treatment options. For instance, according to an article published by Clinical and Translation Oncology in May 2024, the prevalence was 7% in patients with pemphigus vulgaris in Canada. Thus, the growing prevalence of pemphigus vulgaris will significantly boost the therapeutics market by increasing treatment demand and encouraging the development of new and effective therapeutic options.
Additionally, growing research studies on pemphigus vulgaris therapeutics are crucial for advancing treatment options and improving patient outcomes. Increased research efforts lead to a better understanding of disease mechanisms, enabling the development of innovative therapies such as biologics and targeted treatments. As clinical trials demonstrate the efficacy and safety of new interventions, awareness among healthcare providers and patients rises, driving demand for effective therapies.
For instance, study results published by The Journal of Cutaneous Medicine in January 2024 highlight the potential benefits of dapsone and sulfasalazine as adjuvant treatments for pemphigus vulgaris (PV). A systematic review indicated that when these medications were used with standard corticosteroids, they led to clinical improvements in a substantial proportion of patients. Specifically, 58% of patients treated with adjuvant dapsone and 86% receiving sulfasalazine reported clinical improvement. Therefore, the expansion of research studies will significantly stimulate market growth in the forecast period by fostering the development of new treatments, improving patient management, and increasing awareness of the condition.
Therefore, owing to the aforementioned factors, like funding, the rising prevalence of pemphigus vulgaris, and growing research studies on pemphigus vulgaris therapeutics, the market is expected to witness significant growth in the region.
Pemphigus Vulgaris Therapeutics Industry Overview
The pemphigus vulgaris therapeutics market is moderately semi-consolidated in nature due to the presence of several companies operating globally and regionally. Major players in the market are focused on product launches and advancements to expand their presence in the global market. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known, including F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Novartis AG, and GlaxoSmithKline PLC.
Pemphigus Vulgaris Therapeutics Market Leaders
-
AbbVie Inc.
-
F. Hoffmann-La Roche Ltd
-
Pfizer Inc.
-
Novartis AG
-
GlaxoSmithKline plc
- *Disclaimer: Major Players sorted in no particular order
Pemphigus Vulgaris Therapeutics Market News
- August 2024: Topas Therapeutics announced that it was developing PM-203 in Phase I clinical trials for pemphigus vulgaris. The drugs in Phase I for this condition have a high phase transition success rate (PTSR) of 91% for advancing to Phase II.
- June 2024: Cabaletta Bio Inc. released positive initial clinical data from the first two patients treated with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials. These findings were presented at the conference titled "The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease" in Vienna, Austria. Cabaletta is investigating CABA-201 for multiple autoimmune conditions under five disease-specific company-sponsored INDs, including myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG), and pemphigus vulgaris.
Pemphigus Vulgaris Therapeutics Industry Segmentation
As per the scope of the report, pemphigus vulgaris is a rare autoimmune disorder characterized by painful blisters and erosions on the skin and mucous membranes due to the immune system mistakenly attacking proteins that facilitate cell adhesion. This condition can significantly impact the quality of life and requires ongoing treatment, often involving immunosuppressive medications to manage symptoms and prevent complications. Pemphigus vulgaris therapeutics refers to the medical therapies and interventions designed to manage and alleviate the symptoms of pemphigus vulgaris, an autoimmune disorder characterized by blistering skin and mucous membranes.
The pemphigus vulgaris therapeutics market is segmented by treatment and geography. The market is segmented by treatment into corticosteroids, immunosuppressive, intravenous immunoglobulin, antibiotics and antivirals, antifungals, and other treatments. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across the major regions globally. The report offers the market sizes and forecasts in value (USD) for the above segments.
| By Treatment | Corticosteroids | ||
| Immunosuppressive | |||
| Intravenous Immunoglobulin | |||
| Antibiotics and Antivirals | |||
| Antifungals | |||
| Other Treatments | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Corticosteroids |
| Immunosuppressive |
| Intravenous Immunoglobulin |
| Antibiotics and Antivirals |
| Antifungals |
| Other Treatments |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Pemphigus Vulgaris Therapeutics Market Research FAQs
How big is the Pemphigus Vulgaris Therapeutics Market?
The Pemphigus Vulgaris Therapeutics Market size is expected to reach USD 296.35 million in 2025 and grow at a CAGR of 6.30% to reach USD 402.23 million by 2030.
What is the current Pemphigus Vulgaris Therapeutics Market size?
In 2025, the Pemphigus Vulgaris Therapeutics Market size is expected to reach USD 296.35 million.
Who are the key players in Pemphigus Vulgaris Therapeutics Market?
AbbVie Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG and GlaxoSmithKline plc are the major companies operating in the Pemphigus Vulgaris Therapeutics Market.
Which is the fastest growing region in Pemphigus Vulgaris Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Pemphigus Vulgaris Therapeutics Market?
In 2025, the North America accounts for the largest market share in Pemphigus Vulgaris Therapeutics Market.
What years does this Pemphigus Vulgaris Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Pemphigus Vulgaris Therapeutics Market size was estimated at USD 277.68 million. The report covers the Pemphigus Vulgaris Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pemphigus Vulgaris Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Pemphigus Vulgaris Therapeutics Industry Report
Statistics for the 2025 Pemphigus Vulgaris Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pemphigus Vulgaris Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
